Deinove develops antibiotics and bio-based ingredients for cosmetics and nutrition. Deinove researches and develops microbiological technologies for the production of organic acids, antibiotics, ethanol and biofuels.
Deinove owns a large bacterial collection including more than 6000 rare strains collected in different biotopes such as hot springs, volcanos, lagoons, beaches, caves and from various substrates such as wood, water, plant and sand. The company has developed and patented methods for selection and culture or rare bacteria. Deinove’s cell biology lab has characterized their cosmetic activities, such as anti-oxidant, anti-inflammatory and cell regeneration properties.
To improve the production of antibiotic compounds and to achieve optimal performances, the company uses genetic engineering. This involves a custom-made computer-aided design software developed by Deinove and Cad4Bio. The program performs in silico genetic engineering design and operates a robot to perform large-scale DNA cloning and strain construction.
A phase II clinical trial is planned for Deinove’s antibiotic candidate that targets severe gastrointestinal infections caused by Clostridioides difficile. The candidate was also studied by the United States Army Medical Research Institute of Infectious Diseases for treatment against two biothreat agents: Bacillus anthracis which triggers anthrax and Bacillus anthracis which triggers tularemia or rabbit fever.
Phyt-N-Resist was launched in 2018 and it is a colorless carotenoid produced by fermentation of natural sugars by the extremophilic bacterium Deinococcus geothermalis. The product is claimed to fight the effects of aging skin by reducing oxidative stress and accelerating skin regeneration. A second bio-based carotenoid is being developed by Deinove for the cosmetics market. The product targets a dermocosmetic indication that is on the rise.
HEBELYS is an anti-age, anti-wrinkle and moisturizing product produced by fermentation of Sphingomonas bacteria.
Deinove collaborates with two other companies with bacterial strain collections, Naicons and bioMérieux.
Deinove is collaborating with Dow for the development of a cosmetic ingredient derived from bacterial extracts. Deinove plans to develop and optimize a dedicated production process for an extract selected by Dow from their bacterial bank. Deinove collaborates with Greentech for marketing of their skin care product HEBELYS
Deinove is collaborating with Avril in a program aimed at developing a new range of ingredients for animal feed. The ingredients are produced by bacterial fermentation. The product will be marketed as a raw material for animal feed.
